Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares. View IPA analyst ratings or view top-rated stocks .

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 370.6% from the stock's current price. View analysts price targets for IPA or view top-rated stocks among Wall Street analysts .

How have IPA shares performed in 2023?

ImmunoPrecise Antibodies' stock was trading at $5.21 at the beginning of the year. Since then, IPA stock has decreased by 67.4% and is now trading at $1.70. View the best growth stocks for 2023 here .

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 29,000 shares, a decline of 38.3% from the October 31st total of 47,000 shares. Based on an average trading volume of 65,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short. View ImmunoPrecise Antibodies' Short Interest .

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023. View our IPA earnings forecast .

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) released its quarterly earnings data on Thursday, September, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. The company earned $4.26 million during the quarter, compared to analysts' expectations of $3.98 million. ImmunoPrecise Antibodies had a negative net margin of 95.81% and a negative trailing twelve-month return on equity of 35.22%.

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.10%), Rathbones Group PLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ImmunoPrecise Antibodies Stock Price, News & Analysis (NASDAQ:IPA)

$1.70

+0.13 (+8.28%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.51
▼
$1.75
50-Day Range: $1.14
▼
$2.30
52-Week Range: $1.14
▼
$5.90

Volume: 47,464 shs
Average Volume: 60,405 shs
Market Capitalization: $42.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 370.6% Upside
$8.00 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.24
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.35) to ($0.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

284th out of 949 stocks

Pharmaceutical Preparations Industry

117th out of 442 stocks

3.5

Analyst's Opinion

Consensus Rating
ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, ImmunoPrecise Antibodies has a forecasted upside of 370.6% from its current price of $1.70.
Amount of Analyst Coverage
ImmunoPrecise Antibodies has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of ImmunoPrecise Antibodies has been sold short.
Short Interest Ratio / Days to Cover
ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ImmunoPrecise Antibodies has recently decreased by 38.30%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ImmunoPrecise Antibodies does not currently pay a dividend.
Dividend Growth
ImmunoPrecise Antibodies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPA.

2.9

News and Social Media Coverage

News Sentiment
ImmunoPrecise Antibodies has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ImmunoPrecise Antibodies this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for IPA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.
Percentage Held by Institutions
Only 5.71% of the stock of ImmunoPrecise Antibodies is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.35) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ImmunoPrecise Antibodies is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmunoPrecise Antibodies is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmunoPrecise Antibodies has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPA Stock News Headlines

November 30, 2023 | americanbankingnews.com

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Sees Significant Decline in Short Interest

November 27, 2023 | businesswire.com

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 22, 2023 | finance.yahoo.com

ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

November 20, 2023 | benzinga.com

ImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

October 25, 2023 | stockhouse.com

IPA's Subsidiary, BioStrand, Provides an Update on LENSai(TM)

October 25, 2023 | benzinga.com

IPA's Subsidiary, BioStrand, Provides an Update on LENSai™

October 25, 2023 | financialpost.com

IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 20, 2023 | finance.yahoo.com

Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data

October 20, 2023 | finance.yahoo.com

How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research

September 19, 2023 | finance.yahoo.com

ImmunoPrecise Antibodies Announces CFO Transition

September 18, 2023 | nasdaq.com

HC Wainwright & Co. Reiterates ImmunoPrecise Antibodies (IPA) Buy Recommendation

September 18, 2023 | markets.businessinsider.com

ImmunoPrecise Antibodies (IPA) Receives a Buy from H.C. Wainwright

September 17, 2023 | finance.yahoo.com

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2024 Earnings Call Transcript

September 5, 2023 | finance.yahoo.com

IPA Announces Board Refreshment

August 9, 2023 | finance.yahoo.com

IPA Responds to 13D Filing

July 7, 2023 | finance.yahoo.com

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

July 6, 2023 | msn.com

ImmunoPrecise Antibodies's Earnings Outlook

June 29, 2023 | finance.yahoo.com

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.

May 30, 2023 | finance.yahoo.com

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

May 17, 2023 | finance.yahoo.com

IPA to Present at Jefferies Healthcare Conference 2023

April 18, 2023 | benzinga.com

TheStreetReports: Disruptive Technology Stocks in Focus – KAVL, SONM, PBTS, IPA

March 30, 2023 | finance.yahoo.com

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

March 29, 2023 | stockhouse.com

European Patent Office to Grant BioKey's Patent Application for Foundational HYFT® Technology

March 27, 2023 | finance.yahoo.com

European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

March 23, 2023 | finance.yahoo.com

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

See More Headlines

Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/14/2023
Today: 12/01/2023
Next Earnings (Estimated): 12/21/2023
Fiscal Year End: 4/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IPA
CUSIP: N/A
CIK: 1715925
Web: www.immunoprecise.com
Phone: 250-483-0308
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $9.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +370.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,980,000.00
Net Margins: -95.81%
Pretax Margin: -100.04%
Return on Equity: -35.22%
Return on Assets: -25.84%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 2.45
Quick Ratio: 2.10

Sales & Book Value

Annual Sales: $15.61 million
Price / Sales: 2.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.74 per share
Price / Book: 0.98

Miscellaneous

Outstanding Shares: 25,050,000
Free Float: 23,339,000
Market Cap: $42.59 million
Optionable: Not Optionable
Beta: 0.32

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Ilse Roodink
Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
Dr. Barry Neil Duplantis
Vice President of Client Relations
Ms. Kristin Taylor CPA
M.B.A., Chief Financial Officer
Mr. David E. Orton
Chief Operating Officer
Dr. Roland Romijn
Head of General Operations of the Utrecht site of IPA (Europe)

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares.
View IPA analyst ratings or view top-rated stocks.
What is ImmunoPrecise Antibodies' stock price target for 2024?: 2 Wall Street analysts have issued 1 year price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 370.6% from the stock's current price.
View analysts price targets for IPA or view top-rated stocks among Wall Street analysts.
How have IPA shares performed in 2023?: ImmunoPrecise Antibodies' stock was trading at $5.21 at the beginning of the year. Since then, IPA stock has decreased by 67.4% and is now trading at $1.70.
View the best growth stocks for 2023 here.
Are investors shorting ImmunoPrecise Antibodies?: ImmunoPrecise Antibodies saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 29,000 shares, a decline of 38.3% from the October 31st total of 47,000 shares. Based on an average trading volume of 65,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short.
View ImmunoPrecise Antibodies' Short Interest.

When is ImmunoPrecise Antibodies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023.
View our IPA earnings forecast.
How were ImmunoPrecise Antibodies' earnings last quarter?: ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) released its quarterly earnings data on Thursday, September, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. The company earned $4.26 million during the quarter, compared to analysts' expectations of $3.98 million. ImmunoPrecise Antibodies had a negative net margin of 95.81% and a negative trailing twelve-month return on equity of 35.22%.
Who are ImmunoPrecise Antibodies' major shareholders?: ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.10%), Rathbones Group PLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of ImmunoPrecise Antibodies?: Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial